共 76 条
[1]
Stratton IM(2000)Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 405-412
[2]
Adler AI(2009)Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 1765-1772
[3]
Neil HA(2008)10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 1577-1589
[4]
Ray KK(2021)9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021 Diabetes Care 44 S111-S124
[5]
Seshasai SRK(2018)Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2018 2669-2701
[6]
Wijesuriya S(2019)Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary Endocr Pract 25 69-100
[7]
Holman RR(2017)Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial JAMA 318 45-56
[8]
Paul SK(2017)Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes Diabetes Obes Metab 19 1032-1039
[9]
Bethel MA(2018)A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes Diabetes Obes Metab 20 689-697
[10]
Matthews DR(2013)Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials Diabetes Obes Metab 15 175-184